Hot stocks: Brokerages maintain ‘overweight’ rating on DLF, Prestige Estates; KIMS, Torrent Pharma get ‘buy’

Hot stocks: Brokerages maintain ‘overweight’ rating on DLF, Prestige Estates; KIMS, Torrent Pharma get ‘buy’

Brokerages such as JPMorgan maintained its overweight rating on

and

, Kotak Institutional Equities initiated a ‘buy’ on

(KIMS), and

retained ‘buy’ on

.

We have collated a list of recommendations from top brokerage firms with the help of
ETNow and other sources.

JPMorgan on real estate: Overweight on DLF and Prestige Estates

JPMorgan maintained its ‘overweight’ rating on DLF and Prestige Estates with a target price of Rs 490 and Rs 635, respectively.

The residential cycle has turned positive. Market fundamentals continue to be anchored around high affordability and market share continues to gravitate towards listed developers, said the note.

Kotak Institutional Equities on KIMS: Initiate Buy| Target Rs 1,590

Kotak Institutional Equities initiated coverage on KIMS with a ‘buy’ rating and a target price of Rs 1,590. Armed with a solid execution track record, a calibrated expansion approach, and a healthy balance sheet, KIMS is well positioned to build on its strong hospital network in Andhra Pradesh and Telangana with entries in neighbouring states, too.

Despite a 75 per cent addition to its bed capacity over FY2022-26E, the brokerage expects KIMS to report a robust 17.9 per cent Ebitda CAGR in the period.

ICICI Securities on Torrent Pharma: Buy| Target Rs 1,769

ICICI Securities maintained a ‘buy’ on Torrent Pharma with a target price of Rs 1,769. Torrent Pharma (Torrent) is acquiring Curatio Healthcare for a purchase consideration of Rs20 billion.

“While the implied deal valuation of ~7xFY23E sales and ~23x FY23E Ebitda (assuming 30% Ebitda margin) is more expensive than the acquisitions done by the company in the past, there is a significant cross leveraging across the portfolio,” said the note.

Curatio is a leading player in the dermatology space and derives ~84 per cent of its revenue from cosmetic dermatology. The acquisition is expected to enhance the presence of Torrent Pharma in the derma market.

“We believe this acquisition is synergistic to Torrent’s domestic business. However, the acquisition is expected to be EPS dilutive on account of higher interest and depreciation/amortisation charges,” the note added.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

(What’s moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

View Original Article

Free weekly Newsletter

A weekly breakdown of forecasts and trends

Enter your contact info to get The Financial Gambits VIP Newsletter for FREE.

We hate spam as much as you, if you dont like it just unsubscribe and we will never bother you again 

FREE DOWNLOAD

Learn how the spacial web will change the course of our lives and how to identify companies that show the most promise.